share_log

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary

Benzinga Real-time News ·  Sep 12, 2022 18:32
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics' (NASDAQ:MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC). Mersana shares traded as high as 1.79 percent, in a range of $7.48 to $7.94 on day volume of 1.34 million shares, closed regular trading session at $7.48. The company shares traded at $7.40, down 1.07 percent in the after-hours trading session.
  • The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals' (NASDAQ:ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome...
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment